A new study in Brain Sciences shows prolonged use of medical cannabis may help slash the long-term frequency of migraines for the majority of sufferers and reduce medication intake.
Researchers point out that while most pharmaceutical science is based on a single-compound, single-target approach, whole-plant cannabis treatment is multi-compound, according to American Journal of Managed Care.
In addition to THC and CBD, the cannabis plant contains many more active components. Researchers sought to “investigate total doses of individual phytocannabinoids consumed by migraineurs and explore differences in dosage between subgroups of patients based on changes in migraine frequency.”
Only phytocannabinoids consumed with a minimum average concentration of 0.1 gram monthly were analyzed, and doses calculated for each patient.
Researchers were encouraged by the recent findings of the cross-sectional questionnaire-based study, a feeling that is likely shared by the estimated one to two per cent of the global population who suffer from chronic migraines.
The results? Compared to controls, 61 per cent of responders who had received treatment for migraines for an average of three years reported lower current migraine disability, lower negative impact and lower rates of opioid and triptan (drugs commonly used for treatment) consumption, notes the study.